CS1 is found safe, shows signs of efficacy in PAH: Top-line data
Cereno Scientific‘s investigational therapy CS1 was well tolerated and showed signs of clinical benefit in people with pulmonary arterial hypertension (PAH), according to top-line data from a Phase 2a clinical trial. The company plans to start discussions with regulatory authorities and will pursue a pivotal clinical trial to…